Doppel Farmaceutici

Company snapshot

Farmaceutici Damor SpA, founded in 1943, is an Italian pharmaceutical company. Every day, Farmaceutici Damor employees are dedicated to the research, development, manufacturing and marketing of pharmaceutical finished goods and active principal ingredients. Headquartered in Naples, Farmaceutici Damor international presence is guaranteed throughout partnerships with pharmaceutical companies across

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Doppel Farmaceutici. Not investment advice.

• What is Doppel Farmaceutici?

  Dompe' Farmaceutici S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Persistent Corneal Epithelial Defect (PCED), Recent onset Type 1 Diabetes, Spastic Cerebral Palsy, Chronic low back pain, Atopic Keratoconjunctivitis. NovaPharm

• Is Doppel Farmaceutici publicly traded?

  Doppel Farmaceutici appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Doppel Farmaceutici develop or market?

  We link 14 drug profile(s) where Doppel Farmaceutici is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dompe-farmaceutici-s-p-a#company-drugs.

• What are the latest developments for Doppel Farmaceutici?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Doppel Farmaceutici focus on?

  Doppel Farmaceutici focuses on Persistent Corneal Epithelial Defect (PCED), Recent onset Type 1 Diabetes, Spastic Cerebral Palsy based on our analysis of their pipeline programs and drug development activities.